Search

Accessing new eye therapies, protecting vision, improving patients' comfort, developing breaktrough treatments

Home

You are here : Home

Novagali Pharma - Accessing new eye Therapies

Novagali Pharma is an emerging ophthalmic pharmaceutical company that develops innovative products for all segments of the eye.

The company has developed a broad pipeline of innovative products addressing main ocular conditions as well as orphan diseases, thanks to its proprietary technology platforms Novasorb® and Eyeject®.

Press Release

Our commitment to make our site accessible to anyone is based on the WCAG standards. Would you have any suggestion or request do not hesitate to contact us: Make a suggestion.

Press Releases

21 December 2011 Success of the Simplified Cash Tender Offer for the Shares and bons de souscription d’actions of Novagali
Pharma SA by Santen Pharmaceutical Co., Ltd.  Download.pdf

14 November 2011 Novagali Pharma announces its revenue for the first nine months of 2011. Download.pdf

11 October 2011 Santen Pharmaceutical CO., LTD. completes the acquisition of a controlling interest in Novagali Pharma S.A. Download pdf

28 September 2011 Signing of an acquisition of a controlling interest in Novagali Pharma by Santen Pharmaceutical CO., LTD Download pdf

8 September 2011 Catioprost Phase II positive results Download pdf

31 August 2011 First-half results 2011 Download pdf

Discover Cationorm®

Cationorm

An innovative cationic emulsion to relieve dry eye sensation 

  • Moisturization
  • Lubrication
  • Protection

of the eye surface

 Read more

Choose your language